Immunosurveillance, immunodeficiency and lymphoproliferations

Area of Science:

• Immunology
• Oncology
• Virology

Background:

• Malignant lymphomas occur more frequently in individuals with congenital or acquired immunodeficiencies.
• Immunodeficiency-associated lymphoproliferative disorders (IALD) share features like extranodal presentation, rapid progression, B-cell origin, and Epstein-Barr virus (EBV) association.

Purpose of the Study:

• To review the characteristics and incidence of IALD across various immunodeficiency states.
• To explore the role of EBV and immunosuppressive therapies in lymphomagenesis.
• To emphasize the significance of immune surveillance in lymphoid neoplasia.

Main Methods:

• Literature review and synthesis of data on IALD incidence in different patient groups.
• Analysis of IALD classification, including post-transplant lymphoproliferative disorders (PT-LPD).
• Examination of lymphoma subtypes and associations in HIV-infected individuals.

Main Results:

• IALD incidence varies significantly, from 0.7% in X-linked agammaglobulinemia to 12-15% in ataxia telangiectasia.
• PT-LPD incidence ranges from 0.5% to 10% post-transplant and can be hyperplastic, polymorphic, or frankly neoplastic.
• HIV-related lymphomas are predominantly monoclonal B-cell and include Burkitt's and diffuse large cell lymphomas.

Conclusions:

• EBV can drive B-cell proliferation and transformation in T-cell deficient states.
• Immunosuppressive drugs are linked to IALD development, as seen in methotrexate-treated rheumatoid arthritis patients.
• Effective immune surveillance is crucial for preventing lymphoid cancers, suggesting therapeutic implications.